

BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

CIN:L24231GJ1992PLC018237

Website: www.bplindia.in

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2022


Amount Rs. In Lakhs

Sr. No.	Particular	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	A. Revenue from operations	5,902	8,190	3,846	16,701	15,970	21,201
	B. Other Income	348	641	131	1,143	559	778
	Total Income	6,250	8,831	3,977	17,844	16,529	21,979
2	Expenses						
	A. Cost of materials consumed	3,187	5,183	2,438	10,836	10,005	13,272
	B. Purchase of Stock-in-Trade	5	(22)	4	114	133	166
	C. Changes in inventories of finished goods, work-in-progress and stock-in-trade	770	44	(10)	(184)	6	168
	D. Employee benefit expense	451	429	376	1,234	1,148	1,537
	E. Finance costs	79	34	21	139	65	89
	F. Depreciation, depletion and amortisation expense	144	146	164	444	510	666
	G. Other Expenses	1,225	1,637	770	3,336	2,345	3,293
	Total expenses	5,860	7,451	3,762	15,919	14,213	19,192
3	Total profit before tax	390	1,379	215	1,925	2,316	2,788
4	Tax expense						
	Current tax	135	380	82	564	649	830
	Deferred tax	7	15	8	17	(18)	(94)
	Short / (Excess) provision of tax in respect of earlier years						(29)
	Total tax expenses	143	395	90	581	632	706
5	Net Profit / (loss) for period	247	984	125	1,344	1,684	2,081
6	Other comprehensive Income						
	Items that will not be reclassified to profit or loss						
	Remeasurement of defined benefit obligation	(8)	(8)	5	(23)	16	(31)
	Income tax relating to Remeasurement of Defined benefit plans	2	2	(1)	6	(4)	8
	Other comprehensive Income for the year, net of taxes	(6)	(6)	4	(17)	12	(23)
7	Total Comprehensive Income for the period	242	979	129	1,327	1,696	2,058
	Net Profit attributable to:						
	Owners of the company	285	992	134	1,395	1,701	2,105
	Non Controlling Interest	(38)	(7)	(8)	(51)	(17)	(24)
	Other Comprehensive Income attributable to:						
	Owners of the company	(6)	(6)	4	(17)	12	(23)
	Non Controlling Interest	-	-	-	-	-	-
	Total Comprehensive Income for the period						
	Owners of the company	280	987	137	1,378	1,713	2,082
	Non Controlling Interest	(38)	(7)	(8)	(51)	(17)	(24)
	a) Equity Share Capital (Face Value of Rs. 10/- each)						577
	b) Other Equity						16,005
8	Earnings per share						
	Basic (Rs.)	4.94	17.19	2.32	24.16	29.69	36.67
	Diluted (Rs.)	4.94	17.19	2.32	24.16	29.69	36.67

See accompanying notes to the Financial Results

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the group.
- The group has only one segment of activity, namely "Pharmaceuticals."
- The Holding company has acquired 60% equity share capital in Varenyam Biollfsciences Private Limited ("VBPL") during quarter ended on 30th June, 2022. On such acquisition, VBPL has become subsidiary of the company with effect from 28th June, 2022.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

By the order of Board of Director
For Bharat Parenterals Limited



Bharat R. Desai
Managing Director
(DIN: 00552596)

Place : Vadodara
Date : 13th February, 2023



BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

CIN:L24231GJ1992PLC018237

Website: www.bplindia.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2022

Amount Rs. In Lakhs

Sr. No.	Particular	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	A. Revenue from operations	5,902	8,190	3,846	16,701	15,970	21,201
	B. Other Income	395	639	136	1,188	564	778
	Total income	6,297	8,829	3,982	17,889	16,534	21,979
2	Expenses						
	A. Cost of materials consumed	3,187	5,183	2,438	10,836	10,005	13,272
	B. Purchase of Stock-in-Trade	5	(22)	4	114	133	166
	C. Changes in inventories of finished goods, work-in-progress and stock-in-trade	770	44	(10)	(184)	6	168
	D. Employee benefit expense	429	423	373	1,204	1,142	1,526
	E. Finance costs	79	34	21	138	65	89
	F. Depreciation, depletion and amortisation expense	143	145	164	442	510	666
	G. Other Expenses	1,162	1,627	757	3,254	2,317	3,255
	Total expenses	5,774	7,435	3,747	15,804	14,178	19,142
3	Total profit before tax	524	1,394	235	2,085	2,356	2,837
4	Tax expense						
	Current tax	135	380	82	564	649	830
	Deferred tax	7	15	8	17	(18)	(94)
	Short / (Excess) provision of tax in respect of earlier years		-	-			(29)
	Total tax expenses	143	395	90	581	632	706
5	Net Profit / (loss) for period	381	999	145	1,504	1,724	2,130
6	Other comprehensive income						
	Items that will not be reclassified to profit or loss						
	Remeasurement of defined benefit obligation	(8)	(8)	5	(23)	16	(31)
	Income tax relating to Remeasurement of Defined benefit plans	2	2	(1)	6	(4)	8
	Other comprehensive Income for the year, net of taxes	(6)	(6)	4	(17)	12	(23)
7	Total Comprehensive Income for the period	375	993	149	1,487	1,736	2,107
8	Equity						
	a) Equity Share Capital (Face Value of Rs. 10/- each)						577
	b) Other Equity						16,038
9	Earnings per share						
	Basic (Rs.)	6.60	17.30	2.55	26.06	30.09	37.11
	Diluted (Rs.)	6.60	17.30	2.55	26.06	30.09	37.11

See accompanying notes to the Financial Results

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The Company has only one segment of activity, namely "Pharmaceuticals".
- The Company has acquired 60% equity share capital in Varenyam Biolifesciences Private Limited ("VBPL") during quarter ended on 30th June, 2022. On such acquisition, VBPL has become subsidiary of the company with effect from 28th June, 2022.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

By the order of Board of Director
For Bharat Parenterals Limited


Bharat R. Desai
Managing Director
(DIN: 00552596)
Place : Vadodara
Date : 13th February, 2023



Independent Auditor's Review Report on Unaudited Consolidated Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bharat Parenterals Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Bharat Parenterals Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 31st December, 2022 and year to date from 01st April, 2022 to 31st December, 2022 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable



4. The statement includes results of the following entities:
- Innoxel Lifesciences Private Limited
 - Varenyam Biolifesciences Private Limited (Subsidiary w.e.f. 28th June, 2022)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036



Alok Shah

Partner

Membership No. 042005

Place : Vadodara

Date : 13th February, 2023

UDIN : 23042005BGSQUA6305

CNK

& ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Unaudited Standalone Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bharat Parenterals Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Bharat Parenterals Limited ("the Company") for the quarter ended 31st December, 2022 and year to date from 01st April, 2022 to 31st December, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



VADODARA : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007
● Tel: +91 265 234 3483, +91 265 235 4359 ● Email : vadodara@cnkindia.com

MUMBAI - HO : 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. ● Tel: +91 22 6623 0600

Website: www.cnkindia.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

Alok Shah



Alok Shah

Partner

Membership No. 042005

Place: Vadodara

Date: 13th February, 2023

UDIN : 23042005BGSQTW6255